UEEC · XBRL financial data

United Health Products financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (UEEC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1	0	38	0	0	0
Cost of revenue	0	0	—	—	—	—
Cost of goods and services sold	—	0	19	0	—	—
Gross profit	0	0	19	0	—	—
Research and development	245	237	625	599	356	270
Selling, general and administrative	14,604	29,563	2,196	1,828	1,652	1,986
Total operating expenses	14,849	29,801	2,821	2,427	2,008	2,255
Operating income (loss)	(14,849)	(29,801)	(2,802)	(2,427)	(2,008)	(2,255)
Interest expense	210	226	17	41	32	113
Other income (expense)	(863)	(749)	1,115	(197)	6	(414)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(15,711)	(30,549)	(1,688)	(2,623)	(2,002)	(2,669)
Earnings per share, diluted USD per share	—	—	—	(0.01)	(0.01)	(0.01)
Weighted average shares, diluted thousands of shares	—	—	—	239,080	248,173	256,981

Fiscal years (UEEC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	46	22	13	95	169	65
Inventory	70	0	35	34	0	—
Prepaid and other current assets	0	5	23	23	23	40
Total current assets	116	27	71	152	192	105
Property and equipment, net	101	0	—	—	—	—
Right-of-use asset	—	—	0	77	47	15
Total assets	217	27	351	285	270	317
Accrued liabilities	194	3	173	226	—	—
Total current liabilities	1,170	1,169	2,415	1,950	1,641	3,943
Lease liability, non-current	—	—	0	48	15	0
Total liabilities	1,170	1,169	2,415	1,999	2,714	4,193
Accumulated deficit	(41,839)	(72,388)	(74,076)	(76,699)	(78,701)	(81,370)
Total stockholders' equity	(953)	(1,142)	(2,065)	(1,714)	(2,444)	(3,876)
Total liabilities and equity	217	27	351	285	270	317
Common shares outstanding (cover page) thousands of shares	224,000	228,830	234,344	246,833	252,408	258,690

Fiscal years (UEEC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(15,711)	(30,549)	(1,688)	(2,623)	(2,002)	(2,669)
Stock-based compensation	12,723	26,861	483	—	—	—
Net cash from operating activities	(1,326)	(828)	(620)	(2,201)	(1,195)	(1,187)
Purchases of property and equipment	101	0	—	—	—	—
Net cash from investing activities	(101)	0	(41)	(3)	0	0
Proceeds from issuing common stock	1,131	480	176	2,326	—	—
Proceeds from issuing equity	—	—	—	0	66	0
Share repurchases	—	—	50	0	—	—
Repayments of long-term debt	—	—	—	10	—	—
Net cash from financing activities	1,457	804	652	2,286	1,268	1,083

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Positron	357	112	(1,050)*	32.8M	0.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.